RESUMEN
Sympathetic fibres maintain some forms of neuropathic pain, but the underlying mechanisms are poorly understood. Therefore, this study investigated the possible involvement of transient receptor potential ankyrin 1 (TRPA1) and the role of the sympathetic nervous system (involved in sympathetically maintained neuropathic pain) in a model of neuropathic pain induced by sciatic nerve chronic constriction injury (CCI) in mice. Systemic injection of the selective TRPA1 antagonist HC-030031 reversed the mechanical and cold allodynia that was induced by sciatic nerve chronic constriction injury (CCI). Nerve injury also sensitised mice to nociception, which was induced by the intraplantar injection of a low dose of the TRPA1 agonist allyl isothiocyanate without changing TRPA1 immunoreactivity in the injected paw. Furthermore, chemical sympathectomy produced by guanethidine largely prevented CCI-induced mechanical and cold allodynia. CCI also induced a norepinephrine-triggered nociception that was inhibited by an α-adrenoceptor antagonist, norepinephrine transporter block and monoamine oxidase inhibition. Finally, the peripheral injection of HC-030031 also largely reduced CCI-induced norepinephrine nociception and mechanical or cold allodynia. Taken together, the present findings reveal a critical role of TRPA1 in mechanical and cold hypersensitivity and norepinephrine hypersensitivity following nerve injury. Finally, our results suggest that TRPA1 antagonism may be useful to treat patients who present sympathetically maintained neuropathic pain.
Asunto(s)
Neuralgia/metabolismo , Sistema Nervioso Simpático/fisiopatología , Canales de Potencial de Receptor Transitorio/metabolismo , Acetanilidas/farmacología , Analgésicos/farmacología , Animales , Constricción , Modelos Animales de Enfermedad , Hiperalgesia/etiología , Hiperalgesia/metabolismo , Hiperalgesia/fisiopatología , Hiperalgesia/prevención & control , Masculino , Ratones , Neuralgia/etiología , Neuralgia/fisiopatología , Neuralgia/prevención & control , Nocicepción/efectos de los fármacos , Purinas/farmacología , Nervio Ciático/efectos de los fármacos , Nervio Ciático/lesiones , Nervio Ciático/fisiopatología , Sistema Nervioso Simpático/efectos de los fármacos , Canal Catiónico TRPA1 , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidoresRESUMEN
The transient receptor potential ankyrin 1 (TRPA1) has been identified as a relevant target for the development of novel analgesics. Gallic acid (GA) is a polyphenolic compound commonly found in green tea and various berries and possesses a wide range of biological activities. The goal of this study was to identify GA as a TRPA1 antagonist and observe its antinociceptive effects in different pain models. First, we evaluated the ability of GA to affect cinnamaldehyde-induced calcium influx. Then, we observed the antinociceptive and antiedematogenic effects of GA (3-100 mg/kg) oral administration after the intraplantar (i.pl.) injection of TRPA1 agonists (allyl isothiocyanate, cinnamaldehyde, or hydrogen peroxide-H2O2) in either an inflammatory pain model (carrageenan i.pl. injection) or a neuropathic pain model (chronic constriction injury) in male Swiss mice (25-35 g). GA reduced the calcium influx mediated by TRPA1 activation. Moreover, the oral administration of GA decreased the spontaneous nociception triggered by allyl isothiocyanate, cinnamaldehyde, and H2O2. Carrageenan-induced allodynia and edema were largely reduced by the pretreatment with GA. Moreover, the administration of GA was also capable of decreasing cold and mechanical allodynia in a neuropathic pain model. Finally, GA was absorbed after oral administration and did not produce any detectable side effects. In conclusion, we found that GA is a TRPA1 antagonist with antinociceptive properties in relevant models of clinical pain without detectable side effects, which makes it a good candidate for the treatment of painful conditions.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios/farmacología , Antioxidantes/farmacología , Ácido Gálico/farmacología , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidores , Acroleína/análogos & derivados , Acroleína/farmacología , Analgésicos/sangre , Analgésicos/farmacocinética , Analgésicos/uso terapéutico , Animales , Antiinflamatorios/sangre , Antiinflamatorios/farmacocinética , Antiinflamatorios/uso terapéutico , Antioxidantes/farmacocinética , Antioxidantes/uso terapéutico , Edema/tratamiento farmacológico , Edema/etiología , Edema/metabolismo , Ácido Gálico/sangre , Ácido Gálico/farmacocinética , Ácido Gálico/uso terapéutico , Peróxido de Hidrógeno , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Hiperalgesia/metabolismo , Masculino , Ratones , Dolor/tratamiento farmacológico , Dolor/etiología , Dolor/metabolismo , Desempeño Psicomotor/efectos de los fármacos , Nervio Ciático/lesiones , Médula Espinal/metabolismo , Canal Catiónico TRPA1 , Canales de Potencial de Receptor Transitorio/agonistas , Canales de Potencial de Receptor Transitorio/metabolismoRESUMEN
Alzheimer's disease (AD) is biochemically characterized by the occurrence of extracellular deposits of amyloid beta peptide (Aß) and intracellular deposits of the hyperphosphorylated tau protein, which are causally related to the pathological hallmarks senile plaques and neurofibrillary tangles. Monoamine oxidase B (MAO-B) activity, involved in the oxidation of biogenic monoamines, is particularly high around the senile plaques and increased in AD patients in middle to late clinical stages of the disease. Selegiline is a selective and irreversible MAO-B inhibitor and, although clinical trials already shown the beneficial effect of selegiline on cognition of AD patients, its mechanism of action remains to be elucidated. Therefore, we first investigated whether selegiline reverses the impairment of object recognition memory induced by Aß25-35 in mice, an established model of AD. In addition, we investigated whether selegiline alters MAO-B and MAO-A activities in the hippocampus, perirhinal and remaining cerebral cortices of Aß25-35-injected male mice. Acute (1 and 10 mg/kg, p.o., immediately post-training) and subchronic (10 mg/kg, p.o., seven days after Aß25-35 injection and immediately post-training) administration of selegiline reversed the cognitive impairment induced by Aß25-35 (3 nmol, i.c.v.). Acute administration of selegiline (1 mg/kg, p.o.) in combination with Aß25-35 (3 nmol) decreased MAO-B activity in the perirhinal and remaining cerebral cortices. Acute administration of selegiline (10 mg/kg, p.o.) decreased MAO-B activity in hippocampus, perirhinal and remaining cerebral cortices, regardless of Aß25-35 or Aß35-25 treatment. MAO-A activity was not altered by selegiline or Aß25-35. In summary, the current findings further support a role for cortical monoaminergic transmission in the cognitive deficits observed in AD.
Asunto(s)
Trastornos del Conocimiento/tratamiento farmacológico , Selegilina/uso terapéutico , Enfermedad de Alzheimer/inducido químicamente , Enfermedad de Alzheimer/tratamiento farmacológico , Péptidos beta-Amiloides , Animales , Corteza Cerebral/efectos de los fármacos , Trastornos del Conocimiento/inducido químicamente , Modelos Animales de Enfermedad , Hipocampo/efectos de los fármacos , Masculino , Ratones , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/uso terapéutico , Fragmentos de PéptidosRESUMEN
Neuropathic pain is a debilitating condition that is often resistant to common analgesics, such as opioids, but is sensitive to some antidepressants, an effect that seems to be mediated by spinal cord 5-HT3 receptors. Because the analgesic potential of monoamine oxidase-A (MAO-A) inhibitors is understudied, we evaluated the potential antinociceptive effect of the reversible MAO-A inhibitors moclobemide and 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in a mouse neuropathic pain model induced by chronic constriction injury (CCI) of the sciatic nerve. Neuropathic mice showed a decreased mechanical paw withdrawal threshold (PWT) 7 days after lesion compared with the baseline PWT, characterizing the development of hyperalgesia. Moclobemide (100-300 µmol/kg, s.c.) and 2-DMPI (30-300 µmol/kg, s.c.) treatments were able to reverse the CCI-induced hyperalgesia, with 50% inhibitory dose (ID50) values of 39 (18-84) and 11 (4-33) µmol/kg, and maximum inhibition (Imax) values of 88±14 and 98±15%, respectively, at the 300 µmol/kg dose. In addition, we observed a significant increase in the MAO-A activity in the lumbar spinal cord of CCI-submitted mice compared with sham-operated animals. Furthermore, the antihyperalgesic effects of both 2-DMPI and moclobemide were largely reversed by intrathecal injection of the 5-HT3 receptor antagonist ondansetron (10 µg/site). These results suggest a possible involvement of MAO-A in the mechanisms of neuropathic pain and a potential utility of the reversible inhibitors of MAO-A in the development of new therapeutic approaches to treat it.
Asunto(s)
Analgésicos/uso terapéutico , Anisoles/uso terapéutico , Imidazolinas/uso terapéutico , Moclobemida/uso terapéutico , Monoaminooxidasa/metabolismo , Neuralgia/tratamiento farmacológico , Analgésicos/farmacología , Análisis de Varianza , Animales , Anisoles/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/fisiopatología , Imidazolinas/farmacología , Masculino , Ratones , Moclobemida/farmacología , Dimensión del Dolor , Umbral del Dolor/efectos de los fármacos , Pregabalina , Prueba de Desempeño de Rotación con Aceleración Constante , Factores de Tiempo , Ácido gamma-Aminobutírico/análogos & derivados , Ácido gamma-Aminobutírico/farmacología , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
Monoamine oxidase (MAO) inhibitors were the first antidepressant drugs to be prescribed and are still used today with great success, especially in patients resistant to other antidepressants. In this study, we evaluated the MAO inhibitory properties and the potential antidepressant action of 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice. We found that 2-DMPI inhibited both MAO isoforms (K(i) values were 1.53 (1.3-1.8) µM and 46.67 (31.8-68.4) µM for MAO-A and MAO-B, respectively) with 30-fold higher selectivity toward MAO-A. In relation to the nature of MAO-A inhibition, 2-DMPI showed to be a mixed and reversible inhibitor. The treatment with 2-DMPI (100-1000 µmol/kg, s.c.) caused a significant decrease in immobility time in the tail suspension test (TST) without affecting locomotor activity, motor coordination or anxiety-related activities. Conversely, moclobemide (1000 µmol/kg, s.c.) caused a significant increase in immobility time in the TST, which appeared to be mediated by a nonspecific effect on motor coordination function. 2-DMPI (300 µmol/kg, s.c.) decreased serotonin turnover in the cerebral cortex, hippocampus and striatum, whereas dopamine turnover was diminished only in the striatum, and norepinephrine turnover was not changed. The antidepressant-like effect of 2-DMPI was inhibited by the pretreatment of mice with methysergide (2 mg/kg, s.c., a non-selective serotonin receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist) or haloperidol (0.05 mg/kg, i.p., a non-selective dopamine receptor antagonist). These results suggest that 2-DMPI is a prototype reversible and preferential MAO-A inhibitor with potential antidepressant activity, due to its modulatory effect on serotonergic and dopaminergic systems.
Asunto(s)
Anisoles/farmacología , Antidepresivos/farmacología , Monoaminas Biogénicas/metabolismo , Depresión/metabolismo , Imidazolinas/farmacología , Isoenzimas/antagonistas & inhibidores , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Anisoles/antagonistas & inhibidores , Anisoles/uso terapéutico , Antidepresivos/antagonistas & inhibidores , Antidepresivos/uso terapéutico , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Depresión/tratamiento farmacológico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Haloperidol/farmacología , Imidazolinas/antagonistas & inhibidores , Imidazolinas/uso terapéutico , Cinética , Masculino , Metisergida/farmacología , Ratones , Moclobemida/farmacología , Inhibidores de la Monoaminooxidasa/uso terapéutico , Piperazinas/farmacología , Piridinas/farmacologíaRESUMEN
We have recently demonstrated that rodents treated intranasally with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) suffered impairments in olfactory, cognitive and motor functions associated with time-dependent disruption of dopaminergic neurotransmission in different brain structures conceivably analogous to those observed during different stages of Parkinson's disease (PD). On the other hand, the proanthocyanidin-rich fraction (PRF) obtained from the bark of Croton celtidifolius Baill (Euphorbiaceae), a tree frequently found in the Atlantic forest in south Brazil, has been described to have several neurobiological activities including antioxidant and anti-inflammatory properties, which may be of interest in the treatment of PD. The present data indicated that the pretreatment with PRF (10 mg/kg, i.p.) during five consecutive days was able to prevent mitochondrial complex-I inhibition in the striatum and olfactory bulb, as well as a decrease of the enzyme tyrosine hydroxylase expression in the olfactory bulb and substantia nigra of rats infused with a single intranasal administration of MPTP (1 mg/nostril). Moreover, pretreatment with PRF was found to attenuate the short-term social memory deficits, depressive-like behavior and reduction of locomotor activity observed at different periods after intranasal MPTP administration in rats. Altogether, the present findings provide strong evidence that PRF from C. celtidifolius may represent a promising therapeutic tool in PD, thus being able to prevent both motor and non-motor early symptoms of PD, together with its neuroprotective potential.
Asunto(s)
Croton/química , Fármacos Neuroprotectores/farmacología , Trastornos Parkinsonianos/tratamiento farmacológico , Extractos Vegetales/farmacología , Proantocianidinas/farmacología , Administración Intranasal , Animales , Modelos Animales de Enfermedad , Masculino , Fármacos Neuroprotectores/administración & dosificación , Extractos Vegetales/administración & dosificación , Proantocianidinas/uso terapéutico , Ratas , Ratas WistarRESUMEN
OBJECTIVES: To investigate whether there are changes in the activity of the enzymes NTPDase, 5'-nucleotidase, E-NPP and ADA in platelets from patients with rheumatoid arthritis (RA). DESIGN AND METHODS: Thirty-five RA patients diagnosed with RA through American College of Rheumatology criteria, as well as 35 healthy patients were selected. NTPDase, 5'-nucleotidase, E-NPP and ADA activities were verified in platelets isolated from these patients. RESULTS: The results demonstrate that an increase in NTPDase (approximately 100%), 5'-nucleotidase (170%), E-NPP (approximately 100%) and ADA (approximately 45%) activities occurred in RA patients when compared to the control group. CONCLUSIONS: Ours results suggest an increase in the NTPDase, 5'-nucleotidase and E-NPP activities, which could be related to a compensatory organic response to excessive platelet aggregation which occurs during the inflammation. The increased ADA activity found in this work could lead to a decrease in the adenosine concentration in the circulation, which could explain the accelerated atherosclerosis found in patients with RA.